Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Intercept’s CRL Just Continues Upheaval In NASH

Jun 29 2020

• By Joseph Haas

Drugs question mark — The NASH competition may be wide-open again

Related Content

With Phase III NASH Endpoints In Place, Intercept May Reach Market By 2018

May 19 2015

Intercept’s NASH NDA Positions OCA For May 2020 Approval, Then Launch

Sep 30 2019

In NASH, Gilead Swung For The Fences And Struck Out Again

Feb 12 2019

Inventiva Moves Up In NASH, Hitting Multiple Phase IIb Endpoints

Jun 17 2020

RESOLVE-IT Failure Dashes Genfit's NASH Hopes

May 12 2020

Intercept’s NASH Approval Timeline Shuffled Again With FDA Delay

May 22 2020

Related Companies

Intercept Pharmaceuticals, Inc.

Genfit SA

Galmed Pharmaceuticals Ltd.

AbbVie Inc.

Allergan plc

Madrigal Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Inventiva S.A.

Additional Topics

Drug Approval Standards Business Strategies Drug Review Commercial Liver & Hepatic BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window